Business
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR®, as a potential therapy for relapsed
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nLP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR®, as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas.\n\n\n\nLP-284 is the third molecule brought to clinical trials by Lantern Pharma using insights and support from RADR®, Lantern’s AI, machine learning and computational biology platform focused on oncology drug development.\n\n\n\nJapan is the third country to date where a composition of matter patent has been issued for LP-284.\n\n\n\nThe addition of the new patent further strengthens LP-284’s future clinical development and creates pathways for potential future geographic partnerships.\n\n\n\nLantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of $4 Billion USD.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced that the Japan Patent Office (JPO) has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea). The Certificate of Patent entitled “Illudin Analogs, Uses Thereof, and Methods for Synthesizing the Same” covers molecule LP-284, including claims covering the new molecular entity. A Certificate of Patent is issued after JPO examinations have confirmed the merits of a patent request. Lantern values the broad protection this latest patent provides.\n\n\n“The addition of a JPO-issued patent for LP-284 to our intellectual property portfolio strengthens the future of this novel therapeutic for the commercial market and expands the potential for LP-284 to positively impact outcomes for patients with unmet needs in non-Hodgkin’s lymphomas,” said Panna Sharma, CEO and President, Lantern Pharma. “It also supports the use of Lantern’s AI technologies to accelerate the development of novel cancer therapies.”\n\n\nLantern previously received a similar patent on LP-284 from the US Patent and Trademark Office (USP...